CN1148217C - Chinese medicine for treating chronic bronchitis - Google Patents
Chinese medicine for treating chronic bronchitis Download PDFInfo
- Publication number
- CN1148217C CN1148217C CNB011151501A CN01115150A CN1148217C CN 1148217 C CN1148217 C CN 1148217C CN B011151501 A CNB011151501 A CN B011151501A CN 01115150 A CN01115150 A CN 01115150A CN 1148217 C CN1148217 C CN 1148217C
- Authority
- CN
- China
- Prior art keywords
- shares
- radix
- treatment
- chronic bronchitis
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese patient medicine for treating chronic bronchitis, which is a honeyed pill prepared from the following raw materials of the proportion by weight: 8 to 20 shares of Chinese thorowax root, 8 to 20 shares of peach seed, 8 to 20 shares of bitter orange, 6 to 15 shares of safflower, 10 to 30 shares of white paeony root, 8 to 20 shares of angelica, 8 to 20 shares of hemlock parsley, 20 to 40 shares of mongolian dandelion herb, 10 to 30 shares of giant knotweed rhizome, 4 to 10 shares of ephedra, 3 to 10 shares of manchurian wildginger, 20 to 40 shares of membranous milkvetch root, 10 to 25 shares of dahurian angelica, 10 to 30 shares of pinellia tuber, 8 to 20 shares of cassia twig, and 5 to 15 shares of liquoric root. Medicines for warming the lung to reduce watery phlegm are added to the Chinese patent medicine on the basis of medicines for promoting blood circulation to remove blood stasis. The present invention treats the manifestation of the disease, and meanwhile, treats the root cause of disease; the present invention improves the immunological competence of a human body and prevents the recurrence of the disease. Three hundred and four patients of a treatment group are observed in clinical practice, and a control group having one hundred patients is set; the control group takes the Chinese patient medicine, Guilongkechuanning, for 30 days and then the curative effects are calculated; the total effective rate of the treatment group is 98.68%, and the total effective rate of the control group is 74%; the long-term follow-up results of the two groups are compared with each other, and the recurrence rate of the treatment group is obviously lower than that of the control group. The present invention has the advantage of no obvious toxic side effect by pharmacological toxicity tests.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine of controlling chronic bronchitis.
Background technology
The patent No. is 96113159, the authorization notification number is 1064247, denomination of invention discloses a kind of Chinese medicine for the treatment of chronic bronchitis for the patent of invention of " a kind of Chinese medicine and method for making thereof for the treatment of chronic bronchitis ", it what is claimed is a kind of Chinese medicine for the treatment of chronic bronchitis, it is characterized in that: the composition of raw materials of this medicine is: Bulbus Fritillariae Thunbergii 3000～3700g, Flos Lonicerae 1800～2200g, Radix Peucedani 1800～2200g, Cortex Mori 1500～1850g, Semen Armeniacae Amarum 1500～1850g, Radix Platycodonis 900～1100g, Rhizoma Belamcandae 900～1100g, Herba Ephedrae 600～750g, Rhizoma Chuanxiong 150～200g, Radix Glycyrrhizae 150～200g ".This medicine warming the lung heterodyne, Flos Lonicerae phlegm retention cool in nature difficultyization in addition.The ventilation medicine is few, is difficult to improve the phlegm dyspnea symptom.Do not have strong tonic, be difficult to the control recurrence.
Number of patent application is 98110187, notification number is 1196953, denomination of invention is " a kind of Chinese medicine for the treatment of chronic bronchitis, asthma ", its claim is: " Chinese patent medicine of treatment chronic bronchitis, asthma is characterized in that it is that the following weight proportion raw material is formulated: Radix Ginseng 6～12, Herba Ephedrae 8～16, Fructus Mume 8～16, Flos Farfarae 8～16, Semen Armeniacae Amarum 8～16, Fructus Schisandrae Chinensis 8～16, Cortex Cinnamomi 6～12, the Radix Stemonae 6～12, the Rhizoma Pinelliae 6～10, Rhizoma Zingiberis 6～10, dried Alumen 8～14, Radix Glycyrrhizae 6～12." this application lacks the antidote of treatment chronic inflammatory disease, regulating functional activities of vital QI aspect shortcoming, solid receipts are heavier, are difficult to exclusive heresy.
Domestic existing Wang Qingren is controlled the report that blood stasis name side " 'Xue Fu Zhu Yu ' " is used for the treatment of asthma and bronchial asthma, see retrieval serial number 93003464, journal title: Heilungkiang Chinese medicine, reign title and reel number: 1991 (page numbers: 22～23), China classification number: R974, subject classification number: 091, main title: decoction for removing blood stasis treatment the syndrome of dyspnea 66 examples, digest: square substantially: Radix Angelicae Sinensis, the Radix Rehmanniae, Radix Achyranthis Bidentatae, Flos Carthami, withered stalk, Radix Glycyrrhizae, Pheretima, each 15g of Cortex Mori, Radix Bupleuri, Fructus Aurantii, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Bulbus Fritillariae Cirrhosae, each 10g of Herba Ephedrae, Semen Persicae 20g.With the card plus-minus.1 dose of every day, decoction being taken warmly sooner or later.7 days was 1 course of treatment, had a rest and continued clothes in 2 days.This decoction lacks sterilization chronic inflammatory disease medicine, lacks the promoting the flow of QI in the collateral by warming the meridian medicine, and difficulty is recognized the temperature drink that reduces phlegm, elimination asthma.
In addition, the Chinese medicine of treatment chronic bronchitis also has the smart sheet of GUILONG KECHUANNING (tablet), Bulbus Fritillariae Cirrhosae etc., in the treatment based on resolving phlegm and relieving asthma.
It is with depressed lung-energy dispersing that Chinese medicine is always treated chronic bronchitis, and relieving cough and resolving phlegm is main, form such treatment prescription and be mostly to suit the remedy to the case, and controlling symptoms temporarily, and do not reach the purpose of basic healing.
Summary of the invention
The present invention is on the basis of activating blood and removing stasis drug, and meal with wine adds warming the lung dissipating fluid-retention medicine, unimpeded QI and blood, promotion of blood circulation, improve circulation, adjust body function, promote the recovery of defense function, it is basic to treat in treatment mark disease, and the human body immunity improving ability is prevented this palindromia.
The present invention is plus-minus side and making on the basis of name side's " decoction for removing blood stasis ".
The Chinese patent medicine of treatment chronic bronchitis, it is characterized in that: it comprises the medicament that is prepared into by the following weight parts proportion raw material:
The Radix Angelicae Dahuricae 10～25 Rhizoma Pinelliaes 10～30 Semen Persicaes 8～20 Radix Angelicae Sinensis 8～20
Herba Ephedrae 4～10 Herba Asaris 3～10 Ramulus Cinnamomi 8～20 Radixs Astragali 20～40
The Chinese patent medicine of treatment chronic bronchitis, heavy part of proportion optimization scope of its raw material is:
The Radix Angelicae Dahuricae 10～15 Rhizoma Pinelliaes 15～20 Semen Persicaes 10～15 Radix Angelicae Sinensis 10～15
Herba Ephedrae 4～6 Herba Asaris 4～6 Ramulus Cinnamomi 10～15 Radixs Astragali 15～25
The Chinese patent medicine of treatment chronic bronchitis, its parts by weight of raw materials proportioning is:
Radix Bupleuri 8～20 Semen Persicaes 8～20 Fructus Aurantiis 8～20 Flos Carthamis 6～15
The Radix Paeoniae Alba 10～30 Radix Angelicae Sinensis 8～20 Rhizoma Chuanxiongs 8～20 Herba Taraxacis 20～40
Rhizoma Polygoni Cuspidati 10～30 Herba Ephedraes 4～10 Herba Asaris 3～10 Radixs Astragali 20～40
The Radix Angelicae Dahuricae 10～25 Rhizoma Pinelliaes 10～30 Ramulus Cinnamomi 8～20 Radix Glycyrrhizaes 5～15
The Chinese patent medicine of treatment chronic bronchitis, its optimum feed stock weight portion proportioning is:
Radix Bupleuri 10 Semen Persicaes 12 Fructus Aurantiis 12 Flos Carthamis 10
The Radix Paeoniae Alba 20 Radix Angelicae Sinensis 12 Rhizoma Chuanxiongs 10 Herba Taraxacis 30
Rhizoma Polygoni Cuspidati 30 Herba Ephedraes 6 Herba Asaris 9 Radixs Astragali 30
The Radix Angelicae Dahuricae 15 Rhizoma Pinelliaes 20 Ramulus Cinnamomi 12 Radix Glycyrrhizaes 6
Medicament of the present invention be appoint can a kind of pharmaceutics on said dosage form.
Pharmacy optimization honeyed pill of the present invention.
The present invention is prepared into honeyed pill and is used for clinical trial.With 404 routine chronic bronchitis patient random packet, 304 examples are organized in treatment, matched group 100 examples, and two groups compare observation, and the present invention treats the chronic bronchitis determined curative effect, obviously is better than matched group, now is described as follows:
1, clinical data:
Two groups of case 404 examples comprise outpatient's 360 examples (89%), and inpatient's 44 examples (11%) are divided into treatment group and matched group at random.304 examples are organized in treatment, male 188 examples, women 116 examples, 18～29 years old 6 age example; 30～49 years old 45 examples; 50～70 years old 253 examples.Matched group 100 examples, male 69 examples, women 31 examples, 18～29 years old 2 age example; 30～49 years old 19 examples; 50～70 years old 79 examples.Two groups of patients do not have significance (P＜0.05) at aspect significant differences such as sex, age, the course of disease and tcm syndrome differentiation and typings, have comparability.
1.2 diagnostic criteria
All cases are all by the standard of " new Chinese medicine is treated the clinical research guideline of chronic bronchitis " in " new Chinese medicine clinical research guideline ".
(1) Western medicine diagnose standard:
(1) cough, expectoration or the companion annual morbidity of panting continues 3 months, continuous 2 years or more than, and can get rid of other cardiopulmonary disease.(2) annually continue less than 3 months, but possess cough, expectorant, asthma shape and continuous 2 years or more than, clear and definite objective determination is arranged according to (as X line, pulmonary function etc.) diagnosis.According to clinical characters and the cardiopulmonary situation of involving be divided into gently, in, weigh the three degree state of an illness, diagnosis typing is a simple type and pant type.Staging of course of disease is a, chronic bronchitis acute attack stage; Refer to occur in the week purulence or mucous sputum, amount of expectoration showed increased or be mixed with the performance of other inflammation; Or one cough in week, expectorant, asthma shape any one aggravate to severe, or critically ill patient does not obviously increase the weight of the person.The b chronic persistence; Patient has coughing in various degree, expectorant, asthma shape, protracted course of disease; Or the acute attack stage symptom after one month still the end return to the outbreak before level.C, clinical relieving period: refer to patients undergo treatment or natural remission, it is slight that symptom is not enough, keeps more than two months.
(2) traditional Chinese medical science is distinguished the disease typing
A, asthenic cold type: cough, the abundant expectoration color is rare clearly in vain, or pants, and is moving then breathe hard more very, extremity back creeping chill, and frequent micturition or can't help, waist soreness, tastelessness and no thirst, desire for hot drinks, light red tongue is fat tender, and white, slippery and moist fur moistens, deep,thready and forceless pulse.B, phlegm-damp type: the cough with copious phlegm color is white, and is rare or thick, or dyspnea with rapid and short breath, and gastral cavity is vexed, breathes hard, and limbs are stranded heavy, and tastelessness is clamminess, lack of appetite abdominal distention, and ambassador is half congealed, white and greasy fur, soft pulse is sliding.C, phlegm-heat type: cough, the yellow thickness of expectorant, fullness in the chest and shortness of breath, or dyspnea with rapid and short breath, thirst and liking cold drink, yellow urine, big constipation, heating or not hot, yellow fur or white yellow, stringy and rolling pulse or number.D, dryness of the lung type: dry cough, no expectorant or few expectorant, expectorant sticks into silk, is difficult for bringing up mouth and nose drying, big dry stool, red tongue with lack of fluid, few tongue or no fur, thready and stringy pulse or number.
1.2 the standard of including in:
(1) meets all kinds of chronic bronchitis acute attack stages and the chronic persistence patient of above-mentioned diagnostic criteria.
(2) meet above-mentioned diagnosis, PD still belongs to cardiac functional compensatory period to chronic obstructive emphysema or pulmonary heart disease.The pulmonary heart disease heart failure has taken place be able to rectifier through the treatment cardiac insufficiency, most inpatients are this type of.
(3) clinical relieving period patient needs strengthening the body resistance, improves immunologic function person.
(4) tcm clinical practice through dialectical meet aforementioned disease must row Shi Zhizhe.
1.3 exclusion standard
(1) age is in person below 12 years old or more than 70 years old, woman gestationperiod or age of sucking, and allergic constitution.
(2) pulmonary tuberculosis, pulmonary abscess, bronchial asthma, bronchiectasis, heart disease, cardiac insufficiency cause cough, cough up phlegm or pant symptom.
(3) end medication in accordance with regulations can't be judged curative effect, or data not umbra ring curative effect or safety judgement person.
(4) the chronic cardiopulmonary disease heart failure do not correct or exhale decline, the complicated deterioration person of the state of an illness such as soda acid and fluid and electrolyte balance disorder.
2, treatment and observational technique:
2.1 Therapeutic Method: the honeyed pill prescription is formed: Radix Bupleuri 10g, Semen Persicae 12g, Flos Carthami 10g, Radix Angelicae Dahuricae 15g, Rhizoma Chuanxiong 10g, Radix Angelicae Sinensis 12g, Radix Paeoniae Alba 20g, Radix Astragali 30g, Rhizoma Pinelliae 20g, Fructus Aurantii 12g, Herba Taraxaci 50g, Herba Asari 9g, Herba Ephedrae 6g, Rhizoma Polygoni Cuspidati 30g, Radix Glycyrrhizae 6g, Ramulus Cinnamomi 12g, make honeyed pill and weigh 9 grams.Using method: treatment group: other cough suppressing panting calming medicine of stopping using, it is oral to give honeyed pill, each 2 balls, every day 3 times.Matched group: other medicine for the treatment of cough and asthma of stopping using, oral GUILONG KECHUANNING, each 4, every day 3 times.Every group of equal 2 weeks are 1 course of treatment, after finishing the course of treatment, and the statistics curative effect.
2.2 observational technique: (1) cardinal symptom is improved situation: refer to cough, cough up phlegm, pant and infect sign.(2) pulmonary's positive sign changes: refer to variations such as pulmonary's heavy breathing toot sound, rale character, quantity, scope.(3) lung function tests: refer to the per minute maximal voluntary ventilation, observe the variation of airway resistance and pulmonary function.(4) breast X line changes: refer to sign variations such as pulmonary's texture shade.(5) traditional Chinese medical science disease therapeutic effect: refer to treat cross-reference and meet the judgement therapeutic effect.(6) toxic action and untoward reaction; Concrete symptom and sign and relevant inspection abnormal finding.Statistical method: adopt X before and after the treatment
2Check.
3, therapeutic outcome:
3.1 efficacy assessment standard:
With reference to " the clinical research guideline and the national chronic bronchitis specialized conference of new Chinese medicine treatment chronic bronchitis " in the Ministry of Public Health " new Chinese medicine clinical research guideline ", the unified standard of formulating in 1979 is judged.The clinical trial efficacy determination is as follows:
Clinic control (facing control): the symptom of coughing, pant, cough up phlegm is eliminated substantially, and pulmonary roars, and toot sound does not have or significantly minimizing, and the lung dry rale is eliminated, and concurrent obstructive emphysema and patients with cor pulmonale are breathed hard, and cyanosis significantly improves.
Produce effects: cough, cough up phlegm, pant and alleviate or significantly improve, pulmonary's toot sound of roaring significantly reduces, and rhonchi reduces, and moist rale is eliminated, concurrent emphysema, and pulmonary heart disease person's cyanosis of breathing hard obviously improves.
Take a turn for the better: cough, cough up phlegm, panting makes moderate progress, pulmonary rale toot the sound that reduces, roars reduces, and the concurrent emphysema pulmonary heart disease person pulmonary dysfunction such as cyanosis of breathing hard has improvement slightly.
Invalid: the card shape of coughing, pant, cough up phlegm does not have and alleviates, and various rales do not have minimizing, and pulmonary dysfunctions such as the cyanosis of breathing hard do not have improvement, and the symptom wheezing sound increases the weight of.
3.2 two groups of comprehensive therapeutic effects relatively: 304 examples are organized in treatment, total effective rate 98.68%; Matched group 100 examples, total effective rate 74% compares total effective rate and has significant difference (P＜0.01) between group, see Table 1.
3.3 two groups of late results relatively: this group was treated more than 1 year, followed up a case by regular visits to patient's 236 examples altogether, and 180 examples are organized in treatment, matched group 56 examples, its symptom, sign, relapse rate contrast, the long-term effective rate of treatment group as a result 89.44%; Matched group long-term effective rate 37.5%, contrast treatment group long-term effect obviously is better than matched group (P＜0.01) between group, sees Table 2.
3.4 Chinese medical discrimination typing curative effect relatively: Chinese medical discrimination divides 4 types, is example with the treatment group, and wherein the asthenic cold type total effective rate 100%; Phlegm-damp type total effective rate 99.1%; Phlegm-heat type total effective rate 97.37%; Dryness of the lung type total effective rate 89.47%, asthenic cold type, phlegm-damp type effect are better than lung-heat type and dryness of the lung type, see Table 3.
Table 1 liang group comprehensive therapeutic effect relatively
---------------------------------------------------------------------------
The group example number clinic control produce effects invalid effective percentage that takes a turn for the better
The example routine number of the routine number of the routine number of the routine number of number (%) (%) (%) (%) (%)
Treatment organizes 304 124 (40.79) 141 (46.38) 34 (11.18) 4 (0.13) 300 (98.68)
Matched group 100 25 (25) 22 (22) 27 (27) 26 (26) 74 (74)
X
2 8.06 18.58 14.68 66.69 66.69
P ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01
Table 2 liang group late result relatively
----------------------------------------------------------------------
Group example number is followed up a case by regular visits to routine number (%) effective routine number at a specified future date (%) and is recurred routine number (%)
Treatment organizes 304 180/304 (59.21) 161/180 (89.44) 19/180 (10.56)
Matched group 100 56/100 (56) 21/56 (37.50) 35/56 (62.50)
X
2 31.05 53.71
P ＜0.01 ＜0.01
Table 3 Chinese medical discrimination typing curative effect relatively
-----------------------------------------------------------------------------
The syndrome-classification example number clinic control produce effects invalid effective percentage that takes a turn for the better
The example routine number of the routine number of the routine number of the routine number of number (%) (%) (%) (%) (%)
Asthenic cold type 132 52 (39.39) 44 (33.33) 36 (27.27) 0 (0) 132 (100)
Phlegm-damp group 105 34 (32.38) 37 (35.24) 33 (22) 1 (0.095) 104 (99.05)
Phlegm-heat type 38 10 (26.31) 12 (31.58) 15 (39.47) 1 (10.53) 37 (97.37)
Dryness of the lung type 29 5 (26.32) 7 (36.84) 15 (51.72) 2 (10.53) 27 (93.10)
4, pharmacology analysis:
The present invention is with blood circulation promoting and blood stasis dispelling, and regulating functional activities of vital QI is main, is equipped with warming the lung to resolve fluid-retention, and human body immunity improving ability medicine is held concurrently the chronic bronchitis patient and protected healthy energy with Gu, treating both the principal and secondary aspects of a disease, strengthening vital QI to eliminate pathogenic factors when obtaining medical treatment.Semen Persicae in the side, Flos Carthami, Rhizoma Chuanxiong, when being classified as principal agent, blood circulation promoting and blood stasis dispelling is double to nourish blood, modern pharmacological research all contains the Radix Puerariae flavone compounds, but microcirculation improvement is adjusted the effect of body function, Radix Angelicae Sinensis contains ferulic acid, can effectively reduce cell and block, and reduces edema; Radix Bupleuri, Fructus Aurantii, Rhizoma Polygoni Cuspidati regulating functional activities of vital QI, ventilation meridian; Herba Ephedrae, Herba Asari warming the lung to resolve fluid-retention, current 20 warps, particularly Herba Asari consumption surpass conventional restriction, do not see obvious toxic-side effects through pharmacological evaluation, and play the crux effect in warming the lung to resolve fluid-retention, and current 12 pathways are for the operation of QI and blood takes the lead in leading the way; In the heavy dose of utilization side of Herba Taraxaci, clear dampness removing heresy is with detoxifcation, and this medical instrument of tool pharmacological research has broad-spectrum antibacterial action; The cough-relieving of Radix Paeoniae Alba emergency; , Radix Astragali tonifying the lung granulation promoting consolidates and sets upright, and helps gas capable and reach the stasis of blood and loose, thereby improves the blood circulation of diseased region, reduces inflammatory exudation, promotes wound healing, thereby can shorten the course of treatment, improves curative effect of medication, promotes prognosis of disease.
5, beneficial effect:
Show through clinical research, the present invention treats due to the chronic bronchitis tracheitis that cardinal symptom is coughed, expectorant, breathe heavily, inflammation has very significant curative effect.Blood circulation promoting and blood stasis dispelling and qi-activating drug are also used, the gas promoting the circulation of blood is then gone, and gas general rule blood stasis dissipates, and symptoms such as phlegm dyspnea improve thereupon, function is recovered, improved the function of pulmonary ventilation, the improvement of expectoration helps keeping airway patency, makes infection more easy to control, and can transfer the body defensive enginery, strengthen respiratory system and even the disease-resistant evil ability of whole machine body, alleviate inflammatory damage and promote the pathological tissues reparation, full side's compatibility is used, both Zhi Qiben, mend its void, blood stasis dispelling blood simultaneously removes phlegm-damp and takes stopgap measures, treating both the principal and secondary aspects of a disease, strengthening vital QI to eliminate pathogenic factors, all medicine effects are collaborative, bring out the best in each other, effectively prevention of recurrence reverses patient's condition, thereby mitigate the disease reduces anxious number of times and the degree sent out, and reaches the purpose of improving life quality and life-span.Relatively treatment group of two groups of comprehensive therapeutic effects effective percentage is 98.68%, and matched group is 74%.Learn by statistics to handle and have utmost point significant difference (X
2=66.69, P＜0.01).The long-term effect ideal, treatment group long-term effect obviously is better than matched group (X
2=3.05, P＜0.01).Aspect traditional Chinese medical science typing curative effect statistics, the asthenic cold type therapeutic effect is better than obviously that other are various, the warming the lung to resolve fluid-retention of this and Herba Ephedrae, Herba Asari, and the strong mechanism of action of Radix Astragali QI invigorating is coincide.
Acute toxicity testing report of the present invention (Zaozhuang City's medicine inspection is made)
One, medicine
Honeyed pill is prepared by the Drug Manufacturing Room of Zaozhuang Municipal Hospital.
Two, material
Irritate stomach tube, 3% picric acid solution, 5% neutral fuchsin solution, counter balance etc.
Three, animal
30 of Kunming kind white mice, 1～1.5 monthly age, body weight 18～20g, defending the school Animal House by Zaozhuang City first provides.
Four, experimental technique
Get 30 of healthy no pregnant Kunming white mice, male and female half and half, behind the label of weighing, the employing gastric infusion (the 1ml/20g body weight/time), every day three times, continuous 7 days, observe the reaction of animals situation, be index with death, extrapolate the multiple of clinical application amount.
Five, result
This experimental result shows, none death after the white mice medication, and through anatomic observation, each internal organs of animal do not have the material change, and white mice tolerance multiple is more than 249 times.
Six, conclusion
This preparation safety is not seen obvious toxic-side effects.
Quality standard of the present invention
This product raw material is Semen Persicae 12g, Flos Carthami 10g, Radix Angelicae Dahuricae 15g, Fructus Aurantii 12g, Rhizoma Chuanxiong 10g, Radix Glycyrrhizae 6g, Rhizoma Pinelliae 20g, Herba Ephedrae 6g, Herba Asari 9g, Herba Taraxaci 50g, Radix Bupleuri 10g, Radix Paeoniae Alba 20g, Rhizoma Polygoni Cuspidati 30g, Ramulus Cinnamomi 12g, Radix Angelicae Sinensis 12g, Radix Astragali 30g, is processed into honeyed pill.
[character] this product is the big honeyed pills of pitchy.
[discriminating] 1, get this product, put microscopically and observe: the dendritic agglomerate of irregular branch, colourless, meet chloral hydrate liquid and dissolve; Hyphae colorless or light brown, diameter 4-6 μ m.Connect latex dust diameter 12-15 μ m, contain fine particle shape thing.Needle-like calcium oxalate crystal is tiny, and long 10-32 μ m is filled in the parenchyma cell brokenly.Calcium oxalate cluster crystal diameter 18～32 μ m are present in the parenchyma cell, often are arranged in rows, or contain several cluster crystals in a cell.Parenchyma cell contains prism of calcium oxalate around the fibre bundle, forms crystalline cellulose.Parenchyma cell spindle, wall are slightly thick, and atomic thin oblique cross lamination is arranged.The parenchyma taupe brown is to dark brown, and the many shrinkages of cell include brown nuclear shape thing.
2, get this product big honeyed pills 4g, the honeyed pill chopping adds equivalent kieselguhr, grinds well, and adds ethanol 1.5ml, floods 1 hour, and jolting constantly filters, and filtrate is as need testing solution.Other gets Radix Angelicae Sinensis control medicinal material 0.2g, adds ethanol 15ml, shines medical material solution in pairs with legal system.According to thin layer chromatography " 95 editions (appendix VIB) tests of Chinese pharmacopoeia, draw need testing solution 10 μ l, control medicinal material solution 2 μ l, respectively with same silica gel g thin-layer plate on, with normal hexane-ethyl acetate (9: 1) is developing solvent, launch, taking-up is dried, and puts under the ultra-violet lamp (365mm) and inspects.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show identical light blue white fluorescent speckle.
3, get Rhizoma Chuanxiong control medicinal material 0.3g and make control medicinal material solution with need testing solution and above-mentioned control medicinal material solution under discriminating (2) item.According to thin layer chromatography " 95 editions (appendix VIB) tests of Chinese pharmacopoeia, draw and differentiate (2) item need testing solution and each 3 μ l of above-mentioned control medicinal material solution down, respectively with same silica gel g thin-layer plate on, with normal butane-ethyl acetate (9: 1) is developing solvent, launch, take out, dry, put under the ultra-violet lamp (365mm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show a fluorescence speckle of same color.
[inspection] should meet " relevant every regulation under 95 editions (appendix IC) pill items of Chinese pharmacopoeia.
[function with cure mainly] promoting blood circulation to remove obstruction in the collateral, promoting the circulation of QI reduces phlegm, and is used for chronic bronchitis, emphysema, pulmonary heart disease.
[usage and consumption] boiled water takes, one time 2 ball, and 3 times on the one, 2 weeks were 1 course of treatment.
[attention] is not taken by pregnant women.Period in a medicine is avoided eating anything raw or cold, greasy product.
The heavy 9g of [specification] every ball.
Shady and cool place is put in [storage] sealing.
Description of drawings
Fig. 1 is preparation technology's flow chart of the present invention.
The specific embodiment
Embodiment 1 (most preferred embodiment):
Raw material and proportioning:
Radix Bupleuri 10g Semen Persicae 12g Fructus Aurantii 12g Flos Carthami 10g
Radix Paeoniae Alba 20g Radix Angelicae Sinensis 12g Rhizoma Chuanxiong 10g Herba Taraxaci 30g
Rhizoma Polygoni Cuspidati 30g Herba Ephedrae 6g Herba Asari 9g Radix Astragali 30g
Radix Angelicae Dahuricae 15g Rhizoma Pinelliae 20g Ramulus Cinnamomi 12g Radix Glycyrrhizae 6g
[method for making]
1, the processed of raw material is removed the impurity or the thing that goes mouldy, and chopping is cleaned, and Semen Persicae, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Radix Glycyrrhizae beat powder and cross 120 mesh sieves after oven dry under 60 ℃, places dry place standby.
2, the preparation of extractum: all the other clean crude drugs are added water boil 1.5h for 8 times, obtain decocting liquid for the second time, medicinal residues add 8 times of decoctions of water again, and the time is the same, boil altogether 3 times, filter waste, then and 3 medicinal liquids, be condensed into extractum, note frequent stirring when concentrated, in order to avoid coking is rotten.
3, preparing of dry powder: after treating extractum cooling, in time admix Semen Persicae, Rhizoma Chuanxiong,, Radix Angelicae Sinensis, Radix Glycyrrhizae fine powder, mix and mix into the powder shape thoroughly, 60 ℃ of oven dry down, beat powder and cross 120 mesh sieves, place dry shady and cool locating.
4, refined honey: Mel is placed pot interior slow fire heating 2 hours, to being dark brown promptly.
5, pill: the dry powder that system is set adds warm in advance 60 ℃ refined honey, and (ratio of dry powder and refined honey 1: 0.65) mixes thoroughly, and honeyed pill is made in rubbing, and the heavy 9g of every ball is equivalent to the about 7g of crude drug, checks packing.
Embodiment 2:
Raw material and proportioning:
Radix Bupleuri 12g Semen Persicae 15g Fructus Aurantii 15g Flos Carthami 12g
Radix Paeoniae Alba 30g Radix Angelicae Sinensis 15g Rhizoma Chuanxiong 15g Herba Taraxaci 40g
Rhizoma Polygoni Cuspidati 25g Herba Ephedrae 8g Herba Asari 10g Radix Astragali 40g
Radix Angelicae Dahuricae 20g Rhizoma Pinelliae 15g Ramulus Cinnamomi 15g Radix Glycyrrhizae 10g
Present embodiment compares with embodiment 1 that the raw material consumption is big, cost is high, effect strengthens.
Embodiment 3:
Raw material and proportioning:
Radix Bupleuri 15g Semen Persicae 10g Fructus Aurantii 10g Flos Carthami 8g
Radix Paeoniae Alba 10g Radix Angelicae Sinensis 10g Rhizoma Chuanxiong 8g Herba Taraxaci 20g
Rhizoma Polygoni Cuspidati 15g Herba Ephedrae 4g Herba Asari 3g Radix Astragali 20g
Radix Angelicae Dahuricae 10g Rhizoma Pinelliae 10g Ramulus Cinnamomi 8g Radix Glycyrrhizae 6g
It is little that present embodiment and embodiment 1 compare the raw material consumption, and cost reduces, and effect is undesirable.
Claims (3)
1, a kind of Chinese patent medicine for the treatment of chronic bronchitis is characterized in that: it is the medicament that is prepared into by the following weight parts proportion raw material:
Radix Bupleuri 8～20 Semen Persicaes 8～20 Fructus Aurantiis 8～20 Flos Carthamis 6～15
The Radix Paeoniae Alba 10～30 Radix Angelicae Sinensis 8～20 Rhizoma Chuanxiongs 8～20 Herba Taraxacis 20～40
Rhizoma Polygoni Cuspidati 10～30 Herba Ephedraes 4～10 Herba Asaris 3～10 Radixs Astragali 20～40
The Radix Angelicae Dahuricae 10～25 Rhizoma Pinelliaes 10～30 Ramulus Cinnamomi 8～20 Radix Glycyrrhizaes 5～15.
2, the Chinese patent medicine of treatment chronic bronchitis according to claim 1 is characterized in that: its parts by weight of raw materials proportioning is:
Radix Bupleuri 10 Semen Persicaes 12 Fructus Aurantiis 12 Flos Carthamis 10
The Radix Paeoniae Alba 20 Radix Angelicae Sinensis 12 Rhizoma Chuanxiongs 10 Herba Taraxacis 30
Rhizoma Polygoni Cuspidati 30 Herba Ephedraes 6 Herba Asaris 9 Radixs Astragali 30
The Radix Angelicae Dahuricae 15 Rhizoma Pinelliaes 20 Ramulus Cinnamomi 12 Radix Glycyrrhizaes 6.
3, the Chinese patent medicine of treatment chronic bronchitis according to claim 1 is characterized in that: described medicament is a honeyed pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011151501A CN1148217C (en) | 2001-07-17 | 2001-07-17 | Chinese medicine for treating chronic bronchitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011151501A CN1148217C (en) | 2001-07-17 | 2001-07-17 | Chinese medicine for treating chronic bronchitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1337252A CN1337252A (en) | 2002-02-27 |
| CN1148217C true CN1148217C (en) | 2004-05-05 |
Family
ID=4661730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011151501A Expired - Fee Related CN1148217C (en) | 2001-07-17 | 2001-07-17 | Chinese medicine for treating chronic bronchitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1148217C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623494B (en) * | 2009-08-05 | 2011-07-27 | 王永珍 | Chinese ephedra and perilla seed decoction used for chronic bronchitis |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100349596C (en) * | 2005-08-04 | 2007-11-21 | 刘益斌 | Medicinal powder for treating asthma and cough |
| CN102327392B (en) * | 2011-10-14 | 2013-03-27 | 周国生 | Formula of Chinese medicine for treating viral pneumonia |
| CN102641440B (en) * | 2012-05-09 | 2014-07-02 | 万春霞 | Traditional Chinese medicine composition for treating enteric fever trachitis |
| CN103405723B (en) * | 2013-08-23 | 2014-12-31 | 赵秋棠 | Medicine composition for treating recurrent respiratory tract infection of children |
-
2001
- 2001-07-17 CN CNB011151501A patent/CN1148217C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101623494B (en) * | 2009-08-05 | 2011-07-27 | 王永珍 | Chinese ephedra and perilla seed decoction used for chronic bronchitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1337252A (en) | 2002-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1239187C (en) | Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method | |
| CN102058767B (en) | Chinese medicine for treating senile chronic bronchitis and method for preparing pills thereof | |
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1275639C (en) | Medicine for treating women's habitual abortion and threatened abortion | |
| CN1187081C (en) | Compound Chinese medicine for treating extensive cancer | |
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN108635544A (en) | Treat Hashimoto's thyroiditis Chinese medicine composition and its preparation method and application | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1248721C (en) | Chinese medicine composition for treating consumptive disease and its quality control method | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| WO2021169682A1 (en) | Traditional chinese medicine composition, and preparation method therefor and application thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN100457169C (en) | Medicine for treating chronic colitis and its preparing process | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1526440A (en) | Compound Chinese medicine prepn for treating muscular atrophy and amyasthenia and its prepn process | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN1679734A (en) | Chinese medicine composition for treating prostatitis and preparation thereof | |
| CN104491637B (en) | It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application | |
| CN109568484A (en) | A kind of Chinese medicine composition and its preparation method and application for treating cough variant asthma | |
| CN104758733A (en) | External lotion for treating senile vaginitis | |
| CN1209158C (en) | Lung clearing oral liquid preparation for treating viral pneumonia in Children and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C10 | Entry into substantive examination | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |